Entities / Company
Cidara Therapeutics.
company in San Diego, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 22
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
Gone quiet
No new reports in 90+ days-
RBC boosted the price target for Cidara Therapeutics to $75.Speculative1 report
-
Cidara Therapeutics filed an offering with the U.S. Securities and Exchange Commission, with Morgan Stanley and Cantor acting as joint book-running managers.Some support4 reports
-
Cidara Therapeutics was included in the Russell 2000 and 3000 indexes on June 30, 2025.Speculative1 report
-
Cidara Therapeutics, based in San Diego, received Fast Track Designation from the FDA for its therapy CD388.Some support8 reports
No events began in the chosen period. Widen it, or reset.
Around Cidara Therapeutics this week
News at the entities that move Cidara Therapeutics most-
FDA StructuralDBV Technologies is seeking regulatory acceptance for its product from the FDA.Moves Cidara Therapeutics
-
SEC StructuralDHS leans on AbbVie, Altria, and Merck for stock weighting, while the SEC legally requires fiduciaries to prioritize client interests.Moves Cidara Therapeutics
-
Morgan Stanley TransactionalAnalyst rating updates for IONQ as of June 19, 2026, with Jefferies setting a $85 price target and Morgan Stanley lowering theirs to $48.50.Moves Cidara Therapeutics
-
San Diego Shared contextA campaign organized by U.S. Vote Foundation included various food locations across Nashville, Pittsburgh, San Diego, and New York City.Moves Cidara Therapeutics
Connections
The 6 strongest of 22, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
SEC Structural
Cidara Therapeutics is subject to formal regulatory requirements and filing mandates imposed by the SEC.
-
FDA Structural
The FDA provides formal regulatory oversight and grants designations necessary for Cidara Therapeutics' drug development.
-
Merck Structural
Merck acquired Cidara Therapeutics, establishing a current parent-subsidiary relationship.
-
MRK Operational
The relationship is characterized by active market competition, discussed alongside peer groups.
-
Morgan Stanley Transactional
Morgan Stanley served as the joint book-running manager for Cidara Therapeutics during a financing event.
-
San Diego Shared context
Cidara Therapeutics is headquartered in San Diego.
History
Events by the month they beganAugust 2026
1 eventJuly 2026
1 eventJune 2026
4 events- RBC boosted the price target for Cidara Therapeutics to $75.
- Cidara Therapeutics filed an offering with the U.S. Securities and Exchange Commission, with Morgan Stanley and Cantor acting as joint book-running managers.
- Cidara Therapeutics was included in the Russell 2000 and 3000 indexes on June 30, 2025.
- Cidara Therapeutics, based in San Diego, received Fast Track Designation from the FDA for its therapy CD388.